Imaging Genomic Mapping in Glioblastoma
Start-up Funds Colen (PI) 09/04/2012 – 09/03/2017
MD Anderson Cancer Center
The major goals of this research is to correlate MRI Diffusion and Perfusion imaging with underlying glioblastoma genomics for biomarker development and targeted therapeutic discovery.
Targeting Radiogenomics-Derived Core Periostin Correlated Gene Networks in Glioblastoma
338703 Colen (PI) 07/01/2015 – 06/30/2017
Neurosurgery Research & Education Foundation
The major goal is to validate a novel POSTN-associated gene network involved in invasion/edema and cell migration.
Radiome Sequencing of Glioblastoma: Decoding the Imaging Genomic Landscape and Heterogeneity
RSCH11506 Colen (PI) 07/01/2015 – 06/30/2017
Radiological Society of North America
The major goal is to perform radiome sequencing in a preliminary cohort of GBM patients in order to determine the feasibility of technique in guiding precision-based biopsies.
Decoding the Niche Specific Imaging Genomic Landscape and Heterogeneity of Glioblastoma
CABI/GE IN-KIND Research Grant Colen (PI) 03/01/2016 – 02/28/2021
Multi-Investigator Imaging (MI2) Research Award
The major goal is to evaluate tumor heterogeneity in the preclinical mouse model using precision- based image guided surgical biopsies of glioblastoma tumors.
Radiogenomic Screen to Identify Novel Proliferation-associated Glioblastoma Genomic Therapeutic Targets: Discovery and Mechanistic Validation Study
RP160150 Colen (PI) 03/01/2016 – 02/28/2019
Cancer Prevention and Research Institute of Texas - Individual Investigator Research Award
The major goal is to uncover and validate novel, relevant, and clinically meaningful genomic targets that can be subsequently developed into a therapeutic and more personalized treatment for Glioblastoma.
An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations of EGFR Gene Amplification
Industry Contract Colen (PI) 10/23/2015 – 10/22/2017
Puma Biotechnology, Inc.
The major goal of this research is to provide imaging analytics to Puma Biotechnology for brain, lung, and breast tumors of patients on the study.
Southwest Early Clinical Trials - Phase 2 Consortium
3UM1-CA186688-03S1 Yao, James (PI) 03/01/2016 – 02/28/2019
The major goal is to expand the scope of our NCI UM1-funded Southwest Early Clinical Trials (SECT) Consortium to include the long-standing N01-supported Phase 2 program at MD Anderson Cancer Center, and the collaborative Phase 2 program at the University of Colorado Cancer Center.
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular Osteoradionecrosis
1R56 DE025248-01 Lai (PI) 04/01/2016 – 03/31/2021
The major goal is to establish DCE-MRI as an effective clinical outcome measure to identify acute and chronic changes in mandibular bone physiology in cancer patients undergoing definitive irradiation and to evaluate the use of DCE-MRI parameters to monitor ORN response to treatment.